Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
7.43
+0.01 (0.13%)
At close: Feb 11, 2026, 4:00 PM EST
7.00
-0.43 (-5.79%)
Pre-market: Feb 12, 2026, 8:03 AM EST
Vanda Pharmaceuticals Revenue
In the year 2025, Vanda Pharmaceuticals had annual revenue of $216.11M with 8.72% growth. Vanda Pharmaceuticals had revenue of $57.22M in the quarter ending December 31, 2025, with 7.58% growth.
Revenue (ttm)
$216.11M
Revenue Growth
+8.72%
P/S Ratio
2.03
Revenue / Employee
$587,242
Employees
368
Market Cap
439.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 216.11M | 17.33M | 8.72% |
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 161.32M |
| Invivyd | 50.04M |
| Assembly Biosciences | 37.19M |
| LENZ Therapeutics | 17.50M |
| Lineage Cell Therapeutics | 10.82M |
| PureTech Health | 6.39M |
| vTv Therapeutics | 17.00K |
VNDA News
- 16 hours ago - Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - PRNewsWire
- 27 days ago - Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Vanda and Exante Data Combine in Strategic Merger - Business Wire
- 5 weeks ago - Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - PRNewsWire
- 6 weeks ago - Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus - Seeking Alpha
- 6 weeks ago - Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval - Barrons
- 6 weeks ago - US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters